Andra AP fonden Purchases 112,400 Shares of GE HealthCare Technologies Inc. $GEHC

Andra AP fonden boosted its holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) by 8,646.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 113,700 shares of the company's stock after buying an additional 112,400 shares during the period. Andra AP fonden's holdings in GE HealthCare Technologies were worth $7,278,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Banque Cantonale Vaudoise raised its holdings in GE HealthCare Technologies by 16,539.1% in the first quarter. Banque Cantonale Vaudoise now owns 25,957 shares of the company's stock worth $1,849,000 after purchasing an additional 25,801 shares during the period. Allstate Corp grew its holdings in shares of GE HealthCare Technologies by 100.3% in the 4th quarter. Allstate Corp now owns 32,688 shares of the company's stock valued at $2,681,000 after buying an additional 16,365 shares during the period. Auto Owners Insurance Co increased its position in shares of GE HealthCare Technologies by 9,525.4% in the 4th quarter. Auto Owners Insurance Co now owns 33,982,610 shares of the company's stock valued at $278,725,000 after buying an additional 33,629,559 shares in the last quarter. Northside Capital Management LLC increased its position in shares of GE HealthCare Technologies by 26.5% in the 2nd quarter. Northside Capital Management LLC now owns 241,923 shares of the company's stock valued at $15,485,000 after buying an additional 50,634 shares in the last quarter. Finally, Boston Partners raised its stake in GE HealthCare Technologies by 21.7% during the 4th quarter. Boston Partners now owns 4,659,562 shares of the company's stock worth $382,223,000 after buying an additional 830,626 shares during the period. 82.06% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Evercore reiterated an "outperform" rating and set a $84.00 target price on shares of GE HealthCare Technologies in a report on Thursday, July 30th. Royal Bank Of Canada assumed coverage on GE HealthCare Technologies in a research report on Tuesday, June 23rd. They set an "outperform" rating and a $80.00 price target on the stock. BMO Capital Markets started coverage on GE HealthCare Technologies in a report on Wednesday, July 8th. They set a "market perform" rating and a $70.00 price objective on the stock. Piper Sandler reiterated a "buy" rating on shares of GE HealthCare Technologies in a research report on Wednesday, July 29th. Finally, BTIG Research reissued a "buy" rating and set a $79.00 target price on shares of GE HealthCare Technologies in a research note on Thursday, September 17th. Eleven investment analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company's stock. According to MarketBeat.com, GE HealthCare Technologies currently has a consensus rating of "Moderate Buy" and an average price target of $78.39.

GE HealthCare Technologies Stock Down 0.3%

NASDAQ:GEHC opened at $66.09 on Thursday. The company has a debt-to-equity ratio of 0.92, a quick ratio of 0.97 and a current ratio of 1.26. The company has a market cap of $29.85 billion, a PE ratio of 15.16, a PEG ratio of 1.75 and a beta of 0.70. GE HealthCare Technologies Inc. has a 52-week low of $58.75 and a 52-week high of $89.77. The stock has a 50-day simple moving average of $68.44 and a 200 day simple moving average of $67.38.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The company reported $1.13 earnings per share for the quarter, topping the consensus estimate of $1.04 by $0.09. GE HealthCare Technologies had a net margin of 9.33% and a return on equity of 20.12%. The company had revenue of $5.29 billion during the quarter, compared to analysts' expectations of $5.26 billion. During the same period last year, the business earned $1.06 EPS. The business's quarterly revenue was up 5.8% on a year-over-year basis. On average, sell-side analysts expect that GE HealthCare Technologies Inc. will post 4.93 EPS for the current fiscal year.

GE HealthCare Technologies Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be given a $0.04 dividend. This is an increase from GE HealthCare Technologies's previous quarterly dividend of $0.04. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, October 23rd. GE HealthCare Technologies's dividend payout ratio (DPR) is presently 3.21%.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc is a global medical technology, pharmaceutical diagnostics and digital solutions company headquartered in Chicago, Illinois. The company provides products and services designed to support healthcare providers across diagnostic imaging, clinical care and treatment planning.

Its portfolio includes imaging systems such as magnetic resonance imaging, computed tomography, molecular imaging, X-ray and surgical imaging equipment. GE HealthCare also offers ultrasound systems, patient monitoring and care solutions, anesthesia delivery and respiratory care products, maternal and infant care technologies, and healthcare information technology.

The company's Pharmaceutical Diagnostics business develops and supplies contrast media and radiopharmaceuticals used to enhance medical imaging and support the detection and monitoring of disease.

Want to see what other hedge funds are holding GEHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.